Tiverton Asset Management’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Tiverton Asset Management’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-4,531	Closed	-$4.26M	–	169
2016 Q2	$4.26M	Sell	4,531 -36,476	-89%	-$165K	0.18%	115
2016 Q1	$231K	Sell	41,007 -8,993	-18%	-$117K	0.01%	158
2015 Q4	$860K	Sell	50,000 -10,000	-17%	-$238K	0.03%	139
2015 Q3	$1.27M	Sell	60,000 -10,000	-14%	-$343K	0.03%	147
2015 Q2	$3.46M	Hold	70,000	–	–	0.07%	140
2015 Q1	$5.48M	Hold	70,000	–	–	0.11%	118
2014 Q4	$4.24M	Hold	70,000	–	–	0.09%	120
2014 Q3	$2.98M	Hold	70,000	–	–	0.07%	119
2014 Q2	$4.33M	Hold	70,000	–	–	0.1%	110
2014 Q1	$4.55M	Hold	70,000	–	–	0.1%	113
2013 Q4	$3.94M	Hold	70,000	–	–	0.09%	107
2013 Q3	$4.29M	Hold	70,000	–	–	0.1%	104
2013 Q2	$4.09M	Buy	+70,000	New	+$4.31M	0.11%	101

Other funds holding OREX

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Tiverton Asset Management's OREX Position: Q3 2016 in Review

Tiverton Asset Management sold out of Orexigen Therapeutics, Inc. (OREX) in Q3 2016, closing a stake of 4,531 shares — an estimated $4.26M sold.

Tiverton Asset Management first reported a position in OREX in Q2 2013 and held it in 13 quarters. The position peaked at $5.48M in Q1 2015. 55 funds tracked by Wall St. Rank hold OREX as of Q3 2016.

Tiverton Asset Management reported no remaining Orexigen Therapeutics, Inc. position as of Q3 2016 after selling out during the quarter.
Tiverton Asset Management sold 4,531 Orexigen Therapeutics, Inc. shares in Q3 2016, an estimated $4.26M.
Tiverton Asset Management first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 13 quarters.
Tiverton Asset Management's Orexigen Therapeutics, Inc. position peaked at $5.48M in Q1 2015.
55 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q3 2016.

Based on Tiverton Asset Management's 13F filing for Q3 2016, filed 10 Nov 2016.